Great pickup. The US market for ARDS was estimated to be +$800 million to $1 billion prior to COVID so the market opportunity with these increased cases is massive.
Incidentally there is a huge economic impact from ARDS that is not often discussed which concerns unemployment or under-employment. We know the mortality rate for ARDS patients is very high but the statistics I’ve read for survivors is also sobering. Many survivors are unable to return to work for 12-24 months due to the impact of ARDS on the body. This economic burden becomes an added expense to the social system.
The point is any genuine drug for ARDS has a really chance of receiving public subsidies, such as the PBS or equivalent.
IHL Price at posting:
9.5¢ Sentiment: Buy Disclosure: Held